Fermion Technology partners with Simcere Pharmaceutical to develop and commercialise FZ002-037, a clinical-stage non-opioid ...

Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4: Guangzhou, China Monday, January 20, 2025, 11:00 Hrs [IST] ...

As California faces dual threats?natural wildfires and technological hazards?preparedness is no longer optional but essential. Fast Guard Service is at the forefront of protecting critical ...

The global data center colocation and managed hosting services market size is estimated to grow by USD 236.9 billion from ...

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement ...

Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's ...